Antiviral activity, pharmacokinetics and tolerability of IDX 899 [GSK 2248761; IDX 12899] in treatment-naive patients with HIV-1 infections

Trial Profile

Antiviral activity, pharmacokinetics and tolerability of IDX 899 [GSK 2248761; IDX 12899] in treatment-naive patients with HIV-1 infections

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Feb 2012

At a glance

  • Drugs Fosdevirine (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Idenix Pharmaceuticals
  • Most Recent Events

    • 06 Feb 2012 A pooled analysis of this trial and an additional study (NCT00945282) has been published in Antimicrobial Agents and Chemotherapy.
    • 03 Aug 2008 Results presented at the XVII International AIDS Conference 2008.
    • 12 Jun 2008 Results have been reported for the first dosing cohort of eight recipients of IDX 899 800mg, in an Idenix Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top